Navigation Links
Combo therapies tested to overcome drug resistance in melanoma patients
Date:8/2/2011

the same gene. However, Lo determined that was not the case, an important finding because it means that second-generation drugs targeting BRAF would not work and therefore should not be developed, saving precious time and money.

Lo and his team spent two years studying tissue taken from patients who become resistant to try to determine the mechanisms that helped the cancer evade the inhibitors. In the lab, they also developed drug resistant cell lines, in collaboration with another UCLA lab headed by Dr. Antoni Ribas, also a Jonsson Cancer Center researcher. There are still other mechanisms of resistance in melanoma patients with mutated BRAF who are treated with BRAF inhibitors, which UCLA researchers are seeking to uncover and that may provide even more targets for drug therapy. Cancer operates similarly to a criminal seeking to evade his captors, and the small molecule inhibitors are like the police barricades that seek to block escape. When one of the cell signaling pathways driving resistance is blocked, the cancer finds a way to activate another pathway that will drive its growth. If that pathway is blocked, yet another pathway may be activated. The goal is to find a way to block all the pathways helping the cancer evade therapy at once so the cancer cells die before finding a way around the drugs.

In the lab, Lo and his team would apply one drug at a time to the resistant cancer cells and see what route or pathway the cancer used to escape. They then determined what pathway was being used to evade therapy and found an inhibitor for that. In the end, the researchers identified the most optimal combination of molecules to block the pathways PI3K, mTORC and MEK.

"Normal cells have physiologic safety mechanisms to avert death and this is taken to a higher level by the cancer cell to serve its growth agenda, making single agent targeted therapy insufficient," Lo said. "We have to block several roads, which is what is behind our appro
'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles Health Sciences
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Adjuvant combo shows potential for universal influenza vaccine
2. Graphene and spintronics combo looks promising
3. UT Southwestern researchers use drug-radiation combo to eradicate lung cancer
4. Triple-combo drug shows promise against antiviral-resistant H1N1, UAB researcher says
5. New discovery brings customized tuberculosis therapies based on genotype closer to reality
6. Therapies to improve biochemical functions hold promise as treatments for autism
7. Can we get there from here? Translating stem cell research into therapies
8. New mouse model may lead to new therapies for degenerative diseases
9. Study finds therapies using induced pluripotent stem cells could encounter immune rejection problems
10. NIH researchers create comprehensive collection of approved drugs to identify new therapies
11. Go figure: Math model may help researchers with stem cell, cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- Plants have a symbiotic relationship with certain ... nutrients and defend against invaders an important ... vegetables. Now, scientist have discovered that plants may ... ensuring that sprouting plants are colonized from the ... Dame, presented their findings today at the 5th ...
(Date:9/29/2014)... Food and Brand Lab pilot study, published in ... National School Lunch Program (NSLP) by 9% and overall ... Move to Schools (CMTS), an initiative of Michelle Obama,s ... to provide nutrition instruction to students and culinary advice ... event was held in an Upstate New York high ...
(Date:9/29/2014)... the world,s needs to make cheaper and more ... more efficient catalytic materials and processes must be ... Wayne State University, is tackling this problem with ... National Science Foundation. , The nearly $1.5 million ... Electrocatalytic Cascade Reactions," was to Eranda Nikolla, Ph.D., ...
Breaking Biology News(10 mins):Plants prepackage beneficial microbes in their seeds 2Chefs move to schools can increase school meal participation and vegetable intake among students 2Wayne State research aims to develop new, more efficient catalytic materials 2
... Biochemistry and Molecular Biology (ASBMB) has announced that ... the Cleveland Clinic,s Lerner Research Institute and emeritus ... is the recipient of the society,s 2011 Herbert ... The lectureship recognizes outstanding lifetime scientific ...
... Researchers at the University of Oklahoma ... new type of gene therapy to prevent blindness caused by retinitis ... this debilitating disease. ... Federation of American Societies for Experimental Biology (FASEB). The research, ...
... This release is available in German . ... researchers in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research ... decision was made by the DFG,s relevant Grants Committee ... doctoral researchers to complete their training at a highly ...
Cached Biology News:Dr. George Stark receives 2011 Herbert Tabor/Journal of Biological Chemistry Lectureship from ASBMB 2OU researchers find way to prevent blindness in research model for retinitis pigmentosa 2DFG establishes 12 new research training groups 2DFG establishes 12 new research training groups 3DFG establishes 12 new research training groups 4DFG establishes 12 new research training groups 5DFG establishes 12 new research training groups 6
(Date:9/29/2014)... -- The 12th Cold Chain GDP & Temperature Management ... at the John B. Hynes Convention Center. The remarkable ... for a weeklong conference attracting industry executives from around ... to cover the industry,s most pressing topics, with an ... range products, GDP compliance requirements and supply chain integrity. ...
(Date:9/29/2014)...  Perrigo Company plc (NYSE: PRGO ... a portfolio of preclinical research assets, which it ... Corporation plc, to drug discovery and development company, ... will receive an upfront payment in addition to ... future sales derived from the portfolio. ...
(Date:9/29/2014)... Sept. 29, 2014  Xcenda, the strategic consulting ... pharmaceutical sourcing and distribution service companies, recently conducted ... This research was analyzed in an economic model ... with an increase in life years and a ... population-level coffee consumption across the United ...
(Date:9/29/2014)... Westbridge Agricultural Products announced today ... highly effective new tool for organic growers. SUPPRESS™ ... contact herbicide for post-emergent, non-selective weed control for ... The formulation is an emulsifiable concentrate that has ... (OMRI) for use in organic food production. , ...
Breaking Biology Technology:12th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... Oct. 1 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ... the extracellular matrix, today announced that it will,host ... at 12:15 p.m. EDT. A,webcast of the presentations ... PRESENTATIONS, -- Strategic Company Overview, Jonathan ...
... 1 Celsis Rapid Detection, a division of,Celsis ... Frost & Sullivan,2008 North American Growth Strategy Leadership ... the Manufacture and Release of,Pharmaceuticals., "The Celsis ... that enables pharmaceutical companies to significantly reduce,production cycle ...
... and VANCOUVER, Oct. 1 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc ... BioContact Quebec,2008 annual partnering symposium on October 2 ... the Chateau Frontenac in Quebec City. OncoGenex, President ... corporate overview,at the conference, including a discussion of ...
Cached Biology Technology:Halozyme Therapeutics to Host Research Day for Investors and Analysts 2Celsis Receives Frost & Sullivan 2008 Best Practices Award 2Celsis Receives Frost & Sullivan 2008 Best Practices Award 3
...
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... Methylation-specific PCR (MSP) is a ... abnormal gene methylation utilizing small amounts ... an initial bisulfite reaction to modify ... with specific primers designed to distinguish ...
... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... is available as a one-cabinet ...
Biology Products: